Patients with PDD may require special consideration when undergoing drug therapy. Drugs that affect mitochondrial function or energy metabolism must be used with caution. For example, anticonvulsants like valproic acid, which can inhibit mitochondrial enzymes, may worsen the metabolic state of individuals with PDD. Additionally, the altered metabolic state can affect the pharmacokinetics and pharmacodynamics of drugs, necessitating adjustments in dosing or drug selection.
